Citigroup’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-27,200
| Closed | -$21M | – | 6316 |
|
|
2025
Q4 | $21M | Buy |
+27,200
| New | +$18.5M | 0.01% | 1083 |
|
|
2025
Q2 | – | Sell |
-3,500
| Closed | -$2.22M | – | 5863 |
|
|
2025
Q1 | $2.22M | Sell |
3,500
-39,000
| -92% | -$26.8M | ﹤0.01% | 2603 |
|
|
2024
Q4 | $30.3M | Sell |
42,500
-400
| -0.9% | -$336K | 0.02% | 738 |
|
|
2024
Q3 | $45.1M | Buy |
42,900
+400
| +0.9% | +$445K | 0.03% | 575 |
|
|
2024
Q2 | $44.7M | Buy |
42,500
+1,000
| +2% | +$969K | 0.03% | 534 |
|
|
2024
Q1 | $39.9M | Sell |
41,500
-36,600
| -47% | -$34.8M | 0.03% | 581 |
|
|
2023
Q4 | $68.6M | Sell |
78,100
-34,800
| -31% | -$28.7M | 0.05% | 350 |
|
|
2023
Q3 | $92.9M | Buy |
112,900
+60,700
| +116% | +$47.7M | 0.07% | 247 |
|
|
2023
Q2 | $37.5M | Buy |
52,200
+24,700
| +90% | +$19M | 0.02% | 555 |
|
|
2023
Q1 | $22.6M | Buy |
27,500
+13,500
| +96% | +$10.2M | 0.02% | 774 |
|
|
2022
Q4 | $10.1M | Sell |
14,000
-10,000
| -42% | -$7.38M | 0.01% | 1134 |
|
|
2022
Q3 | $16.5M | Buy |
24,000
+10,000
| +71% | +$6.29M | 0.01% | 890 |
|
|
2022
Q2 | $8.28M | Hold |
14,000
| – | – | 0.01% | 1249 |
|
|
2022
Q1 | $9.78M | Sell |
14,000
-26,500
| -65% | -$16.8M | 0.01% | 1311 |
|
|
2021
Q4 | $25.6M | Hold |
40,500
| – | – | 0.01% | 877 |
|
|
2021
Q3 | $24.5M | Buy |
40,500
+5,000
| +14% | +$3.1M | 0.01% | 879 |
|
|
2021
Q2 | $19.8M | Buy |
35,500
+7,500
| +27% | +$3.8M | 0.01% | 1004 |
|
|
2021
Q1 | $13.2M | Sell |
28,000
-78,400
| -74% | -$38.2M | 0.01% | 1196 |
|
|
2020
Q4 | $51.4M | Buy |
106,400
+8,200
| +8% | +$4.43M | 0.03% | 525 |
|
|
2020
Q3 | $55M | Sell |
98,200
-21,700
| -18% | -$13.2M | 0.04% | 413 |
|
|
2020
Q2 | $74.8M | Sell |
119,900
-700
| -0.6% | -$397K | 0.06% | 291 |
|
|
2020
Q1 | $58.9M | Sell |
120,600
-55,600
| -32% | -$22.9M | 0.05% | 307 |
|
|
2019
Q4 | $66.2M | Buy |
176,200
+44,900
| +34% | +$15.1M | 0.05% | 382 |
|
|
2019
Q3 | $36.4M | Buy |
131,300
+4,400
| +3% | +$1.3M | 0.03% | 592 |
|
|
2019
Q2 | $39.7M | Sell |
126,900
-35,500
| -22% | -$11.8M | 0.03% | 552 |
|
|
2019
Q1 | $66.7M | Buy |
162,400
+103,700
| +177% | +$42.7M | 0.06% | 291 |
|
|
2018
Q4 | $21.9M | Buy |
58,700
+9,700
| +20% | +$3.55M | 0.02% | 776 |
|
|
2018
Q3 | $19.8M | Sell |
49,000
-11,600
| -19% | -$4.41M | 0.02% | 838 |
|
|
2018
Q2 | $20.9M | Sell |
60,600
-4,500
| -7% | -$1.41M | 0.02% | 779 |
|
|
2018
Q1 | $22.4M | Sell |
65,100
-18,800
| -22% | -$6.54M | 0.02% | 728 |
|
|
2017
Q4 | $31.5M | Buy |
83,900
+12,500
| +18% | +$5.06M | 0.03% | 615 |
|
|
2017
Q3 | $31.9M | Sell |
71,400
-39,700
| -36% | -$18.9M | 0.03% | 576 |
|
|
2017
Q2 | $54.6M | Buy |
111,100
+61,300
| +123% | +$26.8M | 0.05% | 322 |
|
|
2017
Q1 | $19.3M | Sell |
49,800
-400
| -0.8% | -$148K | 0.02% | 757 |
|
|
2016
Q4 | $18.4M | Sell |
50,200
-1,300
| -3% | -$494K | 0.02% | 820 |
|
|
2016
Q3 | $20.7M | Sell |
51,500
-6,500
| -11% | -$2.61M | 0.02% | 678 |
|
|
2016
Q2 | $20.3M | Buy |
58,000
+23,200
| +67% | +$8.93M | 0.02% | 641 |
|
|
2016
Q1 | $12.5M | Buy |
34,800
+9,600
| +38% | +$3.96M | 0.01% | 851 |
|
|
2015
Q4 | $13.7M | Buy |
25,200
+1,500
| +6% | +$813K | 0.01% | 942 |
|
|
2015
Q3 | $11M | Buy |
23,700
+5,300
| +29% | +$2.85M | 0.01% | 1072 |
|
|
2015
Q2 | $9.39M | Buy |
18,400
+7,900
| +75% | +$3.86M | 0.01% | 1243 |
|
|
2015
Q1 | $4.74M | Buy |
10,500
+9,100
| +650% | +$3.86M | ﹤0.01% | 1776 |
|
|
2014
Q4 | $574K | Buy |
+1,400
| New | +$551K | ﹤0.01% | 3744 |
|
|
2014
Q1 | – | Sell |
-16,000
| Closed | -$4.4M | – | 7169 |
|
|
2013
Q4 | $4.4M | Hold |
16,000
| – | – | ﹤0.01% | 1935 |
|
|
2013
Q3 | $5.01M | Hold |
16,000
| – | – | ﹤0.01% | 1751 |
|
|
2013
Q2 | $3.6M | Buy |
+16,000
| New | +$3.73M | ﹤0.01% | 1924 |
|
Other funds holding REGN
VCM
N
Citigroup's REGN Position: Q1 2026 in Review
Citigroup reduced its Regeneron Pharmaceuticals (REGN) stake by 25% in Q1 2026, selling an estimated $46.4M and leaving 184,691 shares worth $143M. The position accounts for 0.06% of the portfolio, ranked #292.
Citigroup first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $189M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Citigroup held 184,691 shares of Regeneron Pharmaceuticals worth $143M as of Q1 2026.
- Citigroup sold 60,644 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $46.4M.
- Regeneron Pharmaceuticals made up 0.06% of Citigroup's portfolio in Q1 2026, its #292 holding.
- Citigroup first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Regeneron Pharmaceuticals position peaked at $189M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.